ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IDHC Integrated Diagnostics Holdings Plc

0.442
-0.016 (-3.49%)
Last Updated: 09:13:49
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Integrated Diagnostics Holdings Plc LSE:IDHC London Ordinary Share JE00BLKGSR75 ORD USD0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.016 -3.49% 0.442 0.442 0.455 0.444 0.442 0.444 4,066 09:13:49
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Integrated Diagnostics Holdings PLC Notice of Results

28/05/2024 10:42am

RNS Regulatory News


RNS Number : 0981Q
Integrated Diagnostics Holdings PLC
28 May 2024
 

Integrated Diagnostics Holdings Plc


Notice of Results

 

28 May 2024

 

(London) Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading provider of diagnostic services with operations in Egypt, Jordan, Nigeria, Sudan, and Saudi Arabia, will publish its audited results for the quarter ended 31 March 2024 on Thursday, 30 May 2024 at 7am (UK).

 

An analyst and investor call will be hosted at 1pm (UK) | 3pm (Egypt) on Monday, 3 June 2024. You can learn more details and register for the call by clicking on this link.


For more information about the event, please contact: amoataz@EFG-HERMES.com

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Sudan, and Saudi Arabia. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Biolab KSA (Saudi Arabia). With over 40 years of experience, a long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 3,000 diagnostics tests. From its base of 601 branches as of 31 December 2023, IDH served over 8.5 million patients and performed more than 36.1 million tests in 2023. IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group targets expansion in appealing markets, including acquisitions in the Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA).

 

The person responsible for arranging the release of this announcement is Tarek Yehia, Investor Relations Director at IDH.

 

Contact

Tarek Yehia

Investor Relations Director

T: +20 (0)2 3332 1126 | M: +20 10 6882 6678 | tarek.yehia@idhcorp.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORPPURWAUPCUBR

1 Year Integrated Diagnostics Chart

1 Year Integrated Diagnostics Chart

1 Month Integrated Diagnostics Chart

1 Month Integrated Diagnostics Chart

Your Recent History

Delayed Upgrade Clock